The results described in this manuscript demonstrate recruitment of monocytes and NK cells toward tumor cells upon MCP-1 release after enavatuzumab treatment, resulting in activation of these innate effector cells and subsequent ADCC or ADCP on tumor cells. The gene discussed is CCL2; the disease is neoplasm.